Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Earnings for Lyra Therapeutics, Inc. (LYRA)
Earnings in 2023 (TTM): $-62,621,000
According to Lyra Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-62,621,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Lyra Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-62,621,000 | $-62,680,000 |
| 2022 | $-55,265,000 | $-55,278,000 |
| 2021 | $-43,513,000 | $-42,410,000 |
| 2020 | $-22,127,000 | $-22,045,000 |
| 2019 | $-16,306,000 | $-16,093,000 |
| 2018 | $-6,029,000 | $-6,029,000 |